Brokerages Set Ralliant Corporation (NYSE:RAL) PT at $73.00

Ralliant Corporation (NYSE:RALGet Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $73.00.

Several research analysts have recently weighed in on RAL shares. Morgan Stanley upped their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Citigroup raised their price objective on shares of Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Zacks Research raised shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Finally, Barclays increased their target price on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th.

Read Our Latest Research Report on RAL

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RAL. Dodge & Cox raised its position in Ralliant by 13.3% in the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock valued at $621,849,000 after buying an additional 1,434,376 shares during the last quarter. Viking Global Investors LP acquired a new position in Ralliant during the 2nd quarter worth approximately $257,200,000. Millennium Management LLC grew its stake in shares of Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after acquiring an additional 3,147,660 shares in the last quarter. State Street Corp bought a new position in shares of Ralliant during the 2nd quarter worth approximately $213,096,000. Finally, Invesco Ltd. grew its stake in shares of Ralliant by 4.9% during the 4th quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock worth $206,674,000 after acquiring an additional 187,898 shares in the last quarter.

Ralliant Price Performance

Shares of RAL opened at $69.75 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The stock has a 50 day simple moving average of $66.65 and a 200 day simple moving average of $53.94. Ralliant has a 52-week low of $37.27 and a 52-week high of $75.41. The firm has a market capitalization of $7.81 billion and a PE ratio of -6.38.

Ralliant (NYSE:RALGet Free Report) last posted its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Sell-side analysts predict that Ralliant will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s dividend payout ratio is currently -1.83%.

Ralliant Company Profile

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Featured Stories

Analyst Recommendations for Ralliant (NYSE:RAL)

Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.